Email

This Med Tech Innovator Just Doubled, And It Can Do It Again

0 | By Michael A. Robinson

When we last talked last Friday, I showed you how a software executive founded biotech company Veeva Systems Inc. (VEEV) and turned his expertise in cloud software into a 1,253% gain for investors.

That’s over the last seven years, mind you. Enough to turn $25,000 into $338,250 and up to $1.35 million in the next four years.

Here’s the thing. If you’re a “set-and-forget” investor happy to match the S&P 500, you’ve come to the wrong place.

We’re here to crush the market with the foremost innovative tech leaders

Over the seven years I’m talking about, the S&P 500 gained a very respectable 128%.

Not bad. Unless you compare it to VEEV.

Veeva beat it by a staggering 879%.

Today, I’m following up to show you why Veeva is such a great company and is set to double again in about 21 months…

Who Is Peter Gassner?

Last time we spoke, I told you about Peter Gassner, Veeva’s founder. As you may recall, his background is in software, not biotech.

He spent years at International Business Machines Corp. (IBM) and other software firms, before eventually becoming senior vice president at Salesforce.com (CRM).

Gassner was a powerful force behind Salesforce’s very successful IPO in 2004 was the first time most investors had ever heard of cloud-based software.

Just three years later, Gassner took that cloud expertise and decided to found Veeva and bring the cloud to biotech.

It became a transformational moment for the $1.2 trillion drug sector by simplifying some of its toughest tasks beyond drug discovery. And the cloud allowed for fast and convenient collaboration

The Biotech Challenge

See, despite the huge potential and importance of biotech, the drug industry is still filled with time-consuming and expensive headaches.

It costs a small fortune for a company to build software to track the testing, sales, and all of the regulatory data they must have on hand. Especially as all this data has to have state-of-the-art security to comply with strict patient privacy laws.

Consider that the Biotechnology Innovation Organization, or BIO, a trade group, looked at 7,400 drug programs by 1,103 companies and just 9.6% of the drugs scientists discover ever get approved for sale.

On top of that, a few years back the Tufts Center for the Study of Drug Development found that it cost $1 billion to get a new drug to market.

Tufts has since updated that study to reveal the field is only getting tougher. It now forecasts that the average these days takes 12 years to go from discovery to commercial launch.

When you factor in the impact of failed trials, the average cost of getting a new drug to the public is a staggering $2.5 billion.

That’s partly because of the complexity of all the data and paperwork that has to be stored and filed correctly. Any mistake there can lead to failed trials, missed opportunities, or even mistakes.

And over so many years, homemade software will tend to break.

The Veeva Solution

So, it’s no wonder that biotech leaders are on the lookout for what Veeva offers. The firm’s cloud tools help clients manage the entire clinical suite, from lab research results, trial data, and sales and patient outcomes.

The platform covers everything from collecting and verifying data to ensuring clients are ready for any government inspections. Not to mention that it’s all cross-referenced and not on paper, which saves huge amounts of time – and allows researchers to spot connections that would have remained hidden before.

That fact alone helps explain why so many top-tier firms are now Veeva clients. We’re talking more than 800 firms across the globe, up 23% in a little more than a year.

The list reads like a Who’s Who of the field – AstraZeneca PLC (AZN), Biogen Inc. (BIIB), GlaxoSmithKline (GSK), Eli Lilly & Co. (LLY), and Shire Pharma Group Plc.

Plenty More Ahead

Make no mistake. Veeva is still on the move.

In the most recent quarter, sales grew 29% as per-share profits climbed by 38%.

Over the past three years, Veeva has grown per-share earnings by an average 41%. At that rate, earnings will double again in roughly 21 months.

And remember, in almost exactly the last seven years, the stock has gained 1,253%. That’s enough to turn $25,000 into $338,250.

But earnings on are pace to double once again in 21 months, or two doubles in less than four years. Since it’s a good bet that stock price will double when earnings do, that would be when our investment would have grown to $1.35 million

Just to be conservative, let’s cut that in half, meaning we would make $676,500 in a total of 11 years – from just one great tech leader.

Add it all up and you can see why I say it’s so important to be investing in tech.

Just a handful of stocks like VEEV can make you a millionaire in just a few years’ time.

And while it might be too late to cash in on VEEV’s 1,253% gains of the past seven years, there are still plenty of other stocks out there just waiting to take off in value.

In fact, you can get exclusive access to a strategy that can give you a chance at 1,000% gains over less than thirty days on September 8 at 1 P.M. at the Profit Revolution event.

All you have to do is click here to save yourself a spot.

Cheers and good investing,

Michael A. Robinson

Leave a Reply

Your email address will not be published. Required fields are marked *